Papillary thyroid cancer v600 positive mutation, mainly refers to papillary thyroid cancer gene mutation, can choose molecular targeted therapy, chemotherapy, surgery, iodine 131 treatment and so on. 1. Molecular targeted therapy: clinically, sorafenib can be used for molecular targeted therapy, and if it has already developed into advanced stage, lenvatinib can be used for treatment, which is more suitable for patients who have not received systematic treatment. 2. Chemotherapy: for papillary thyroid cancer chemotherapy, adriamycin, cisplatin and other anti-tumor drugs are usually used. 3. Surgery: mainly according to the stage of thyroid cancer, as well as the metastasis and spread of the cancer cells, suitable surgery plan can be chosen. It includes total or subtotal thyroidectomy, and clearing the surrounding lymph nodes. 4. Iodine 131 treatment: in order to remove the remaining tumor cells as much as possible after surgery, iodine 131 treatment can be used after surgery. Papillary thyroid cancer is the mildest type of cancer, which can be treated early and has a good prognosis, but it should be carried out under the guidance of specialized doctors. After surgery, it may lead to insufficient or no secretion of thyroxine, and need to take levothyroxine tablets for replacement therapy. During the treatment period, regular review should be conducted to find out the metastatic spread of cancer cells and thyroxine in the body.